Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression - Trial NCT06084923
Access comprehensive clinical trial information for NCT06084923 through Pure Global AI's free database. This phase not specified trial is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto and is currently Not yet recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 73 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gruppo Italiano Malattie EMatologiche dell'Adulto
Timeline & Enrollment
N/A
Dec 01, 2023
Dec 01, 2025
Primary Outcome
The 12 and 24-month Time To Next Treatment (TTNT) measured from the time of ibrutinib discontinuation due to reasons other than CLL progression, Richter syndrome, malignancy or death, or lost to the follow-up.
Summary
The goal of this observational study is to assess in the cohort of CLL patients enrolled in
 the front-line GIMEMA LLC1114 study who discontinued ibrutinib the time to subsequent
 treatment. The main question it aims to answer is:
 
 • The 12 and 24-month TTNT measured from the time of ibrutinib discontinuation due to reasons
 other than CLL progression, Richter syndrome, malignancy or death, or lost to the follow-up.
 
 Participants will be observed for the duration of the study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06084923
Non-Device Trial